| Jul 29 |
CEL-SCI Announces Closing of $10.8 Million Offering
|
| Jul 26 |
CEL-SCI Announces Pricing of $10.8 Million Offering
|
| Jul 26 |
CEL-SCI stock rallies 40% on Multikine study analysis results
|
| Jul 26 |
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
|
| Jul 8 |
CEL-SCI names Robert Watson as chair
|
| Jul 8 |
CEL-SCI Appoints Robert Watson as Chairperson of the Board
|
| Jun 18 |
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
|
| Jun 6 |
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
|
